Cited by 492Smoking Behavior and CessationCardiac Health and Mental HealthAcute Myocardial Infarction Research

The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease

Open access
Joseph, Anne M., Norman, Suzanne M., Ferry, Linda H., Prochazka, Allan V., Westman, Eric C., Steele, Bonnie G., Sherman, Scott E., Cleveland, Minot +3 more·1996·New England Journal of Medicine

Abstract

BACKGROUND: Transdermal nicotine therapy is widely used to aid smoking cessation, but there is uncertainty about its safety in patients with cardiac disease. METHODS: In a randomized, double-blind, placebo-controlled trial at 10 Veterans Affairs medical centers, we randomly assigned 584 outpatients (of whom 576 were men) with at least one diagnosis of cardiovascular disease to a 10-week course of transdermal nicotine or placebo as an aid to smoking cessation. The subjects were monitored for a total of 14 weeks for the primary end points of the study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive heart failure); the secondary end points (admission to the hospital for other reasons and outpatient visits necessitated by increased severity of heart disease); any side effects of therapy; and abstinence from smoking. RESULTS: There were 48 primary and 78 secondary end points noted in a total of 95 subjects. At least one of the primary end points was reached by 5.4 percent of the subjects in the nicotine group and 7.9 percent of the subjects in the placebo group (difference, 2.5 percent; 95 percent confidence interval, -1.6 to 6.5 percent; P=0.23). In the nicotine group, 11.9 percent of the subjects had at least one of the secondary end points, as compared with 9.7 percent in the placebo group (difference, 2.2 percent; 95 percent confidence interval, -2.2 to 7.4 percent; P= 0.37). After 14 weeks the rate of abstinence from smoking was 21 percent in the nicotine group, as compared with 9 percent in the placebo group (P=0.001), but after 24 weeks the abstinence rates were not significantly different (14 percent vs. 11 percent, P= 0.67). CONCLUSIONS: Transdermal nicotine does not cause a significant increase in cardiovascular events in high-risk outpatients with cardiac disease. However, the efficacy of transdermal nicotine as an aid to smoking cessation in such patients is limited and may not be sustained over time.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199612123352402

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Hwang SL, Waldholt M. Heart attacks reported in patch users still smoking. Wall Street Journal. June 19, 1992:B1.

Cited by

Sorted by citations

Authors
Joseph, A. M., Norman, S. M., Ferry, L. H., Prochazka, A. V., Westman, E. C., Steele, B. G., Sherman, S. E., Cleveland, M., Antonuccio, D. O., Hartman, N., & McGovern, P. G.
Affiliations
  • University of Minnesota (US)
  • Kansas City VA Medical Center (US)
  • VA Loma Linda Healthcare System (US)
  • United States Department of Veterans Affairs (US)
  • Durham VA Medical Center (US)
  • VA Sepulveda Ambulatory Care Center (US)
  • Portland VA Medical Center (US)
  • VA West Los Angeles Medical Center (US)
Venue
New England Journal of Medicine
Published
1996-12-12
Volume
335
Issue
24
Pages
1792-1798
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2320130521
Cited by
492
References
32
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 12 · 2020: 13 · 2019: 8 · 2018: 12 · 2017: 11 · 2016: 14 · 2015: 9 · 2014: 14 · 2013: 14 · 2012: 24
FWCI
11.91
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
transdermal nicotine, smoking cessation, heart disease, cardiovascular safety, myocardial infarction, congestive heart failure, cardiac arrhythmias, smoking abstinence, veterans, nicotine therapy
MeSH terms
Administration, Cutaneous, Aged, Aged, 80 and over, Analysis of Variance, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Male, Middle Aged, Nicotine, Smoking Cessation, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review